BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
Sean Werner, Chief Technology Officer of BioLife Solutions, sold 111 shares of the company's common stock on 08/26/2025 at $25.44 per share under a pre-existing Rule 10b5-1(c) trading plan. The Form 4 shows the sale was to satisfy tax withholding obligations tied to the vesting of restricted stock and the reporting person retained 26,384 shares of common stock after the transaction. The filing is signed by Sean Werner on 08/28/2025 and indicates the Form is filed by one reporting person.
Insider sale under 10b5-1 plan: Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 590 shares of BioLife Solutions Inc. (BLFS) on 08/26/2025 at a price of $25.44 per share. After the sale, Mr. Wichterman beneficially owned 185,218 shares, held directly. The filing states the sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. The Form 4 is signed by the reporting person on 08/28/2025.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 219 shares of common stock on 08/26/2025 at $25.44 per share under a pre-established Rule 10b5-1(c) plan. The filing states the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported transaction, the reporting person beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.
The sale was made pursuant to a 10b5-1 trading plan adopted 02/24/2022, which the filer checked on the form to indicate pre-planned execution; the Form 4 is signed and dated 08/28/2025.
Insider sale under a pre-established plan: Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported the sale of 354 shares of common stock on 08/26/2025 at a price of $25.44 per share. After the transaction, Berard beneficially owned 134,264 shares, held directly. The filing states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations from restricted stock vesting. The Form 4 is a routine disclosure of a planned sale; no new grants, options, or derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 10,000 shares of BLFS common stock on 08/25/2025 at a weighted average price of $25.53 per share (individual trade prices ranged from $25.46 to $25.63). After the sale, the reporting person beneficially owned 124,618 shares. The Form 4 was signed on 08/27/2025 and discloses the sale as a direct disposition. The filer notes the reported price is a weighted average from multiple transactions and offers to provide the number of shares sold at each price upon request.
Form 144 notice for BioLife Solutions, Inc. (BLFS) reports a proposed sale of 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $255,265 and an approximate sale date of 08/25/2025. The shares were acquired on 03/03/2025 as restricted stock that vested under a registered plan and the payment type is recorded as compensation. The filer reports no securities sold in the past three months and includes the required representation that they are not aware of undisclosed material adverse information.
Casdin-related entities reported a 14.0% stake in BioLife Solutions (BLFS), owning 6,707,165 common shares based on 47,905,265 shares outstanding as of July 31, 2025. The shares are held by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin, who together share voting and dispositive power over the reported shares. The Reporting Persons state the shares were purchased for investment using the Fund's working capital and that no borrowed funds were used other than ordinary working capital borrowings. They state no current plans to pursue corporate control changes but reserve the right to recommend actions or cooperate with others to maximize shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of 500,000 shares of BioLife Solutions, Inc. (BLFS) on 08/15/2025 at a reported price of $24.40 per share. After the transaction, the Master Fund beneficially owned 6,707,165 shares, held indirectly. The Form 4 lists related reporting entities and individuals: Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin, each identified as a director or related to the Master Fund, and signatures are dated 08/21/2025. The filing includes a disclosure that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
BioLife Solutions, Inc. reported the results of its 2025 annual meeting of stockholders held on August 20, 2025. Stockholders of record as of June 23, 2025, holding 47,835,214 shares of common stock, were eligible to vote, and 43,063,037 shares were present or represented by proxy.
All seven director nominees – Roderick de Greef, Catherine Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, Tony Hunt, and Timothy Moore – were elected to serve until the 2026 annual meeting. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,403,856 votes for and 2,060,352 against. In addition, they ratified the Audit Committee’s appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 43,024,019 votes for and 11,169 against.
BioLife Solutions, Inc. (BLFS) Rule 144 notice reports a proposed sale of 500,000 common shares through BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000. The filing states total shares outstanding of 47,905,265. The securities to be sold were acquired in three cash purchases: 250,000 on 07/02/2020, 100,000 on 12/16/2020, and 150,000 on 04/30/2024. The filer discloses prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 and 500,000 shares on 08/11/2025 with stated gross proceeds.